Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by BlaineBorgon Jun 03, 2021 10:07pm
160 Views
Post# 33327405

RE:RE:RE:RE:RE:here we go

RE:RE:RE:RE:RE:here we goGo a step further in your thought process. They're dying by the thousands per day in India. Think global pandemic. But you are making my point. No urgency. If it were, we would have gotten news by now. Not on day 60 or day 70 of the process at the last possible minute. They did the same thing with the Final data for covid-19. They waited until the last day of Q1 to release mediocre data and the stock got harshly punished because of it. Also, the CEO stated he doubts the data has the ability to get emergency approval. That was the CEO of the company who said that. He doesn't exude confidence in the data or the ability to deliver on what he sold everyone for months on end. The market clearly doesn't have confidence based on the share price remaining at 52 week lows. The market is onto the fluffy news releases that never tell us what we are waiting to hear. Like a real deal in the making or data from the chronic cough study. They continue to miss the moment of inflection to create the necessary interest to move the neddle in a permanent and meaningful way. Always a day late and a dollar short. That's not going to lift confidence in those who dot the I's and cross the T's about investing even in wild and no fundamentals penny stocks like Algernon. They keep stacking up things to do and nothing has gotten done in a way that makes a difference. 
<< Previous
Bullboard Posts
Next >>